Prof. Dr. med. et phil. nat. Markus Jörger
chief of service
Medizinische Onkologie und Hämatologie · Dept. I
International, multicenter, open-label, phase II study to investigate the efficacy and safety of multiple doses of IMAB362 in patients with advanced adenocarcinoma of the stomach or the lower esophagus
Jan 26, 2011IMAB362 ist ein chimärer, muriner/humaner, monoklonaler IgG1-Antikörper. IMAB 362 bindet mit hoher Affinität an das CLND18.2-Antigen, ein Transmembranprotein, das auf differenzierten Magenepithelzellen und auf ~ 70 % der Zelloberfläche von Magenkarzi...
Clinical Studies - Jan 26, 2011 - Jun 30, 2012
Completed
Project leader: Köberle Dieter
Members: Inauen Roman, Jörger Markus
First in human clinical development of the MC4 receptor antagonist scFv 1E8a (Obexia) - MFZ 2010_012
Nov 10, 2010For patients with cancer cachexia new mechanism-based pharmacological interventions are required, in addition to a standardized palliative cancer care and basic cachexia management approach. The melanocortin system is one of the important targets for...
Clinical Studies - Nov 10, 2010 - Dec 31, 2011
Aborted
Project leader: Jörger Markus, Strasser Florian
Members: Haile Sarah, Hundsberger Tom
FLOxTox: Assessment of the Polygenic Basis of Adverse Reactions to 5-Flourouracil/Leucovorin/Oxaliplatin of Colorectal Cancer Patients Using a Pathway Approach
Aug 31, 2009Unter der Behandlung der beiden Chemotherapien FOLFOX (5 FU, Oxaliplatin) und XELOX (Capecitabine, Oxaliplatin) entwickeln ca. 10% der PatientInnen schwere Arzneimittelnebenwirklungen. Das Enzym Dihydropyrimidin-Dehydrogenase (DPD) ist massgeblich am...
Clinical Studies - Aug 31, 2009 - Aug 31, 2011
Completed
Project leader: Jörger Markus
Members: Frick Petra, Ruedlinger Luzia, Köberle Dieter, Inauen Roman